



**State of New Jersey**  
**CANNABIS REGULATORY COMMISSION**  
P.O. BOX 216  
TRENTON, N.J. 08625-0216

PHILLIP D. MURPHY  
*Governor*

SHEILA Y. OLIVER  
*Lt. Governor*

DIANNA HOUEYOU, *Chair*  
SAMUEL DELGADO, *Vice Chair*  
KRISTA NASH, *Commissioner*  
MARIA DEL CID-KOSSO, *Commissioner*  
CHARLES BARKER, *Commissioner*  
JEFF BROWN, *Executive Director*

**RESOLUTION 2022-29**  
**ACCEPTANCE OF CERTIFICATION FOR ALTERNATIVE TREATMENT CENTER**  
**TERRASCEND NJ TO EXPAND OPERATIONS TO THE**  
**ADULT PERSONAL-USE CANNABIS MARKET**

**WHEREAS**, the authority to regulate and enforce activities related to medicinal cannabis previously was vested in the New Jersey Department of Health (“the Department”), and now vests in the New Jersey Cannabis Regulatory Commission (“the Commission”) pursuant to P.L. 2019, c.153; and

**WHEREAS**, pursuant to N.J.S.A. 24:6I-46a(3)(a)(ii), in order for an Alternative Treatment Center (“ATC”) to begin engaging in the cultivation, manufacturing, retailing, wholesaling, distributing, or delivery of personal-use cannabis items, the Commission shall not require a full application from the ATC; and

**WHEREAS**, pursuant to N.J.S.A. 24:6I-46a(3)(a)(iii), an ATC “shall not engage in activities related to the growing, manufacturing, wholesaling, transporting or delivering of cannabis or cannabis items until it has certified to the [C]ommission that that it has sufficient quantities of medical cannabis and medical cannabis products available to meet the reasonably anticipated needs of registered qualifying patients, and the [C]ommission has accepted the alternative treatment center’s certification”; and

**WHEREAS**, pursuant to N.J.S.A. 24:6I-46a(3)(a)(iv), in determining whether to accept, an ATC’s certification, the Commission “shall assess patient enrollment, inventory, sales of medical cannabis and medical cannabis products, and any other factors determined by the commission through regulation”; and

**WHEREAS**, pursuant to N.J.A.C. 17:30-7.1(b), the Commission requires submission of certain documentation and certifications from any ATC wishing to engage in the cultivation, manufacturing, retailing, wholesaling, distributing, or delivery of personal use cannabis items, including but not limited to:

1. A letter of intent notifying the Commission of the licenses sought by the ATC;
2. Municipal approval for each class of license sought by the ATC;
3. Evidence that the ATC has sufficient quantities of medical cannabis and medical cannabis products to meet the reasonably anticipated needs of

registered qualifying patients, and that the ATC shall not make any operational changes that reduce access to medical cannabis for current and newly registered qualifying patients;

4. A list of owners, principals, management services contractors, financial sources, and vendor-contractors associated with the proposed cultivation, manufacturing, retailing, wholesaling, distributing, or delivery of personal-use cannabis items, as applicable; and
5. An attestation signed by a bona fide labor organization stating that the ATC has entered into a labor peace agreement with such bona fide labor organization; and

**WHEREAS**, pursuant to the Executive Director's Expanded Alternative Treatment Center memorandum of November 23, 2021, each currently permitted ATC was reminded of the overall process, requirements, fees, and review procedure that the ATCs must satisfy to be granted approval from the Commission to expand operations into the adult personal-use market; and

**WHEREAS**, on February 4, 2022, Executive staff for the Commission held an informational call with the current group of ATCs to address outstanding questions with the certification process and to ensure that the group was aware of all privileges and prohibitions regarding expanding ATC operations; and

**WHEREAS**, pursuant to N.J.A.C. 17:30-7.1(c), the Commission has assessed the following criteria before determining whether to accept each ATC's certification:

1. Total qualifying patient enrollment in the Statewide medical cannabis program;
2. Qualifying patient enrollment at the ATC that has submitted for certification;
3. Statewide inventory of medical cannabis items and inventory of the ATC that has submitted for each certification;
4. Statewide sales of medical cannabis and medical cannabis products, as well as the sales at the ATC that has submitted for certification;
5. The current medical cannabis canopy of the ATC that has submitted for certification;
6. The total medical cannabis canopy needed to serve the qualifying patients of the ATC that has submitted for certification, on an ongoing basis;
7. The total medical cannabis canopy needed to serve the total number of qualifying patients in the medical cannabis program on an ongoing basis; and
8. The operational plans and capacity of the ATC that has submitted for certification to maintain or expand medical cannabis access for qualifying patients; and

**WHEREAS**, pursuant to N.J.A.C. 17:30-7.1(d), the Commission shall only accept a certification from an ATC when an ATC has proven, by clear and convincing evidence, that

engaging in the cultivation, manufacturing, retailing, wholesaling, distributing, or delivery of cannabis items, as applicable, shall not adversely impact access for registered qualifying medical cannabis patients and shall not adversely impact the availability of medical cannabis or medical cannabis products; and

**WHEREAS**, pursuant to N.J.A.C. 17:30-7.1(e) the Commission shall approve an expanded ATC in accordance with the regulation where:

1. An ATC has submitted complete and accurate and verifiable information, as determined by the Commission;
2. The Commission accepts the ATC's certifications pursuant to N.J.A.C. 17:30-7.1(b) through (d); and
3. The ATC pays the Expanded ATC certification fee pursuant to N.J.A.C. 17:30-7.17; and

**WHEREAS**, TerrAscend NJ sent its initial submission to convert to an Expanded ATC on December 13, 2021. During the April 11, 2022, special meeting, the Commission voted to approve TerrAscend NJ's expansion into the personal use market and issued the following licenses:

1. A Class 1 Cannabis Cultivator and a Class 2 Cannabis Manufacturer license for the 130 Old Denville Road, Boonton, NJ location; and
2. Class 5 Cannabis Retailer licenses for the 1865 Springfield Avenue, Maplewood, NJ and 55 South Main Street, Phillipsburg, NJ locations; and

**WHEREAS**, on May 10, 2022, TerrAscend NJ submitted a request to include an additional retail location in its expanded operations; and

**WHEREAS**, the Commission has determined that TerrAscend NJ has submitted complete and accurate and verifiable information for the additional retail location;

**NOW, THEREFORE, BE IT RESOLVED** by the New Jersey Cannabis Regulatory Commission pursuant to N.J.S.A. 24:6I-46a(3)(a)(ii) and N.J.A.C. 17:30-7.1, the following ATC has satisfied the requirements set forth in the regulation and the Commission has determined to accept their request to expanded its personal-use cannabis operations to the following additional retail location, pending the payment of the requisite Expanded ATC certification fee:


ATC	Location(s)	License Requested
TerrAscend NJ	200 Route 17 South, Lodi, NJ	Class 5 Cannabis Retailer

Pursuant to N.J.A.C. 17:30-7.1(g) and (h), and prior to commencement of operations in the adult personal-use market at the above-listed location, the expanded ATC must complete any necessary construction or preparation of expansion, comply with all terms and conditions contained in its Final Agency Decision, and satisfy a Commission onsite inspection to ensure that the premises, operations, and procedures are consistent with the documentation and certifications required, as

well as compliant with the law and regulations.

The expanded ATC shall maintain compliance with applicable regulations and shall comply with any continued or future onsite assessments to evaluate current or future undertakings or guarantees included in the expanded ATC's certification materials.

Submitted by:



Dianna Houenou, Chair

**CERTIFICATION**

I hereby certify that the foregoing is a true copy of the Resolution adopted by the Cannabis Regulatory Commission at its meeting held on the 24<sup>th</sup> day of May, 2022.



Christopher Riggs, Chief Counsel

<b>Vote on the Approval of This Resolution</b>	<b>Motion</b>	<b>Second</b>	<b>Yes</b>	<b>No</b>	<b>Abstain</b>	<b>Absent</b>
Commissioner Barker	X		X			
Commissioner Del Cid-Kosso			X			
Commissioner Delgado		X	X			
Chairwoman Houenou			X			
Commissioner Nash			X			